Lenzetto, an estradiol spray, has been shown to reduce frequency and severity of hot flushes in post-menopausal women
News
GSK, Sanofi join forces to develop COVID-19 vaccine
Sanofi will contribute its S-protein COVID-19 antigen, GSK its pandemic adjuvant technology
Genetic Alliance UK launches COVID-19 advice hub
The hub offers ‘life-saving health guidance’ to millions of vulnerable people in the UK.
SMC accepts four medicines for NHS use
Biogen’s Famprya, Sanofi’s Suliqua, Janssen’s Stelara and Shionogi Rizmoic will be funded on the NHS in Scotland
AZ to test Calquence for COVID-19
The moves follows ‘strong scientific evidence’ indicating the role of the BTK pathway in the production of inflammatory cytokines
Gov’t streams £14bn into public services in COVID-19 response
More than £14 billion from the Coronavirus emergency response fund will go towards public services
AZ, MSD’s Koselugo bags US approval
The drug is the first in the world to be approved to treat this rare and debilitating genetic condition
Lilly to test Olumiant, LY3127804 against COVID-19
The RA drug Olumiant will be assessed in patients hospitalised with the virus
Avacta and Cytiva team up for COVID-19
The firms will develop and manufacture an Affimer-based point-of-care rapid test for screening large populations for COVID-19 infection
Tiziana develops delivery tech for COVID-19 treatment
This technology enables direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs
Circassia pulls plug on AZ agreement
Circassia will shed its debt to AstraZeneca under the move
FDA, EMA accept Opdivo-Yervoy filings in lung cancer
The filing is based on data from the CheckMate-9LA trial, which showed a benefit in overall survival
Bayer wins EU approval for Eylea syringe
The syringe provides a new streamlined method to administer Eylea
Oxford Biomedica joins consortium for promising COVID-19 vaccine
According the firm, the vaccine candidate is one of the most promising in development
Expanded EU approval for Takeda’s Alunbrig
The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option
